Immunotherapies are a variety of therapeutics used to treat cancer by stimulating the body's own immune system making it more capable of killing cancer cells. Immunotherapies work differently that traditional cancer treatments, like chemotherapy and radiotherapy, because they target the immune system opposed to directly killing cellular tissue.
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Abstract Learning Objectives Define a tertiary lymphoid structure in human cancer Describe the tumor microenvironment factors that influence the formation of tertiary lymphoid structures Ide...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...
Date: October 26, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the pa...
Learning Objectives 1. Identify 3 obstacles that inhibit the immune cell response to cancer. 2. List 3 aspects of T cells antitumor function that can be improved with costimulatory signals....
Date: December 2, 2021 Time: 8:00am (PDT), 11:00am (EDT) Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To ad...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput fl...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
New insights on the pathogenesis of COVID-19 7:00–7:30 pm PDT Presented By: Olaf Rötzschke, PhD The SIgN Mass Cytometry Platform (MCP) was originally established by Evan Newell, P...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
With the recent successes of immunotherapies, a fresh breeze of optimism in the fight against cancer has reinvigorated the industry. Perhaps the greatest legacy will be the realization of th...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
Abstract Learning Objectives Define a tertiary lymphoid structure in human cancer Describe the tumor microenvironment factors that influence the formation of tertiary lymphoid structures Ide...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...
Date: October 26, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the pa...
Learning Objectives 1. Identify 3 obstacles that inhibit the immune cell response to cancer. 2. List 3 aspects of T cells antitumor function that can be improved with costimulatory signals....
Date: December 2, 2021 Time: 8:00am (PDT), 11:00am (EDT) Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To ad...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput fl...
T cells exquisitely discriminate between antigenic and self-peptide ligands presented on major histocompatibility complexes (pMHCs) despite subtle differences in affinities. This aspect of a...
Date: August 26, 2021 Time: 8:00am (PDT), 11:00am (EDT) My translational research program focuses on approaches to enhance the natural killer (NK) cell response to cancer, with an emphasis o...
Learning Objectives: 1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity 2. Explain how PD-1 blockade leads...
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
Date: May 26, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenged in that only a minority of patie...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
New insights on the pathogenesis of COVID-19 7:00–7:30 pm PDT Presented By: Olaf Rötzschke, PhD The SIgN Mass Cytometry Platform (MCP) was originally established by Evan Newell, P...
Date: Time: Over the last couple of years, it has become apparent that affinity-tuned CAR T cells display enhanced expansion and prolonged persistence in patients and that this strategy can...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Date: September 16, 2020 Time: 9:00am PTD, 12:00pm EDT Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant ce...
With the recent successes of immunotherapies, a fresh breeze of optimism in the fight against cancer has reinvigorated the industry. Perhaps the greatest legacy will be the realization of th...
Opens in a new windowOpens an external siteOpens an external site in a new window